ES2074769T3 - Procedimiento para la elaboracion de un preparado farmaceutico con, al menos, dos principios activos diferentes y uso de un preparado de este tipo. - Google Patents

Procedimiento para la elaboracion de un preparado farmaceutico con, al menos, dos principios activos diferentes y uso de un preparado de este tipo.

Info

Publication number
ES2074769T3
ES2074769T3 ES92110679T ES92110679T ES2074769T3 ES 2074769 T3 ES2074769 T3 ES 2074769T3 ES 92110679 T ES92110679 T ES 92110679T ES 92110679 T ES92110679 T ES 92110679T ES 2074769 T3 ES2074769 T3 ES 2074769T3
Authority
ES
Spain
Prior art keywords
preparation
mixtures
different
tablets
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92110679T
Other languages
English (en)
Inventor
Gerhard Dr Gergely
Wolfram Dr Tritthart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2074769T3 publication Critical patent/ES2074769T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

UNA SOLUCION ACUOSA O DISPERSION PARA TOMA ORAL DE AL MENOS DOS SUSTANCIA ACTIVAS FARMACEUTICAS DISTINTAS SE PREPARA DE TAL FORMA, QUE AL MENOS CONTIENE DOS MEZCLAS DE DESCOMPOSICION Y/O EFERVESCENCIA EN TABLETAS, O CORRESPONDIENTEMENTE EN FORMA GRANULADA, DE LAS QUE CADA UNO CONTIENE UNA SUSTANCIA ACTIVA DIFERENTE O UNA COMBINACION DE SUSTANCIA ACTIVAS DIFERENTES. LAS MEZCLAS SON DISUELTAS O SUSPENDIDAS EN UNA CANTIDAD DE AGUA DETERMINADA. AL MENOS UNO DE LOS COMPRIMIDOS O TABLETAS PUEDE SER UTILIZADO COMO PIEZA FRAGMENTO, Y AL MENOS UNA DE LA MEZCLAS TIENE UN PESO INFERIOR A 2.000 MG., PREFERENTEMENTE MENOS DE 1.500, Y EN PARTICULAR MENOS DE 1.000 MG. ESPECIALMENTE UNA DE LAS MEZCLA CONTIENE UN DIURETICO, EN PARTICULAR HIDROCLOROTIACIDO Y/O FLUOROSEMIDA Y AL MENOS UNA DE LAS OTRAS MEZCLAS CONTIENE UN BLOQUEADOR BETA Y/O UN VASODILADATOR, EN PARTICULAR NAFTIDROFURILO, CALCIO ANTAGONISTA, RETARDADOR ACE, BLOQUEADOR ALFA-1. TALES MEZCLAS DE DESCOMPOSICION Y/O EFERVESCENCIA SE UTILIZAN DE FORMA PREFERENTE EN COMPRIMIDOS O EN FORMA GRANULADA PARA EL TRATAMIENTO DE LA HIPERTONIA. OTRAS COMBINACIONES DE SUSTANCIAS ACTIVAS SON APROPIADAS PARA EL TRATAMIENTO DE ASMA, OSTEOPOROSIS, O PARA LA TERAPIA ULCUS.
ES92110679T 1991-07-01 1992-06-25 Procedimiento para la elaboracion de un preparado farmaceutico con, al menos, dos principios activos diferentes y uso de un preparado de este tipo. Expired - Lifetime ES2074769T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH194491 1991-07-01

Publications (1)

Publication Number Publication Date
ES2074769T3 true ES2074769T3 (es) 1995-09-16

Family

ID=4222248

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92110679T Expired - Lifetime ES2074769T3 (es) 1991-07-01 1992-06-25 Procedimiento para la elaboracion de un preparado farmaceutico con, al menos, dos principios activos diferentes y uso de un preparado de este tipo.

Country Status (8)

Country Link
US (1) US5393531A (es)
EP (1) EP0521388B1 (es)
JP (1) JPH05186332A (es)
AT (1) ATE122228T1 (es)
CA (1) CA2072533A1 (es)
DE (1) DE59202126D1 (es)
DK (1) DK0521388T3 (es)
ES (1) ES2074769T3 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK9200258U4 (da) * 1992-03-11 1993-07-23 Merck & Co Inc Farmaceutisk præparat indeholdende enalapril til brug mod hypertension
ZA963590B (en) * 1995-05-10 1996-11-19 Adcock Ingram Ltd Pharmaceutical composition
US5994348A (en) 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
EP1378234A1 (en) * 1996-05-17 2004-01-07 MERCK & CO. INC. Effervescent bisphosphonate formulation
US5853759A (en) * 1996-05-17 1998-12-29 Merck & Co.. Inc. Effervescent alendronate formulation
EP1820497A3 (en) * 1996-05-17 2009-07-22 Merck & Co., Inc. Effervescent bisphosphonate formulation
WO1997044017A1 (en) * 1996-05-17 1997-11-27 Merck & Co., Inc. Effervescent bisphosphonate formulation
US5770215A (en) * 1997-01-06 1998-06-23 Moshyedi; Emil Payman Multivitamin/vascular occlusion inhibiting composition
EP1175903A3 (en) * 1997-07-22 2002-12-18 MERCK & CO. INC. Method for inhibiting bone resorption
DE19814257A1 (de) 1998-03-31 1999-10-07 Asta Medica Ag Brauseformulierungen
US20010039262A1 (en) * 2000-04-26 2001-11-08 Balaji Venkataraman Methods and compositions for the treatment of cardiac indications
DE10038364A1 (de) * 2000-08-05 2002-05-02 Hexal Ag Pharmazeutische, Ramipril enthaltende Brauseformulierung
JP2003221335A (ja) 2001-10-26 2003-08-05 Dey Lp 慢性閉塞性肺疾患の症状を緩和するためのアルブテロールおよびイプラトロピウム吸入溶液、システム、キットおよび方法
US6702997B2 (en) 2001-10-26 2004-03-09 Dey, L.P. Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma
US20030140920A1 (en) * 2001-10-26 2003-07-31 Dey L.P. Albuterol inhalation soultion, system, kit and method for relieving symptoms of pediatric asthma
US20030203930A1 (en) * 2001-10-26 2003-10-30 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
US20030191151A1 (en) * 2001-10-26 2003-10-09 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
US7488496B2 (en) * 2002-03-06 2009-02-10 Christer Rosen Effervescent compositions comprising bisphosphonates and methods related thereto
EP1490024B1 (en) * 2002-03-06 2012-01-18 EffRx Pharmaceuticals SA Effervescent compositions comprising alendronate
AU2005249794A1 (en) 2004-06-04 2005-12-15 Teva Pharmaceutical Industries, Ltd. Pharmaceutical composition containing irbesartan
PL2252273T3 (pl) * 2008-03-19 2017-07-31 Ratiopharm Gmbh Stała kompozycja farmaceutyczna zawierająca niepeptydowy związek antagonistyczny receptora angiotensyny II i środek moczopędny

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1075470A (en) * 1964-07-01 1967-07-12 Miles Lab Effervescent tablet
US3906107A (en) * 1972-09-08 1975-09-16 Abbott Lab Aminoalkyl sulfate esters with diuretic activity
DE2743702A1 (de) * 1977-06-03 1978-12-14 Pharmaceutical Export Promotio Abmagerungs- oder schlankmacher- zubereitung und verfahren zu ihrer herstellung
US4289751A (en) * 1979-06-29 1981-09-15 Merck & Co., Inc. Effervescent enteric-coated formulation of soluble form of erythromycin and therapeutic use thereof
AT373492B (de) * 1981-12-14 1984-01-25 Arcana Chem Pharm Verfahren zur herstellung von brausetabletten
US4684516A (en) * 1983-08-01 1987-08-04 Alra Laboratories, Inc. Sustained release tablets and method of making same
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4832956A (en) * 1985-09-25 1989-05-23 Gerhard Gergely Disintegrating tablet and process for its preparation
IT1201136B (it) * 1987-01-13 1989-01-27 Resa Farma Compressa per uso farmaceutico atta al rilascio in tempi successivi di sostanze attive
US5073377A (en) * 1988-11-03 1991-12-17 Miles Inc. Method of preparing oral dosage forms with a granulating composition
CA2021548A1 (en) * 1989-09-01 1991-03-02 Ronald Nash Duvall Effervescent cold or sinus allergy medicine composition having reduced sodium content
US5126348A (en) * 1989-09-26 1992-06-30 The University Of Colorado Foundation, Inc. Bioavailability enhancers

Also Published As

Publication number Publication date
US5393531A (en) 1995-02-28
ATE122228T1 (de) 1995-05-15
EP0521388A1 (de) 1993-01-07
DE59202126D1 (de) 1995-06-14
DK0521388T3 (da) 1995-09-11
EP0521388B1 (de) 1995-05-10
JPH05186332A (ja) 1993-07-27
CA2072533A1 (en) 1993-01-02

Similar Documents

Publication Publication Date Title
ES2074769T3 (es) Procedimiento para la elaboracion de un preparado farmaceutico con, al menos, dos principios activos diferentes y uso de un preparado de este tipo.
BR9913945A (pt) Composição farmacêutica para o tratamento de distúrbios agudos por meio de administração sublingual, e, processo para o tratamento de distúrbios agudos
BR9908030A (pt) Composição farmacêutica compreendendo uma ou mais unidades de dose oralmente ministráveis, e, processos para prepará-la, para uso da mesma, e para tratar uma condição ou distúrbio médico em um indivìduo em que tratamento com um inibidor da ciclooxigenase-2 é indicado
AR003116A1 (es) Compuestos triciclicos utiles para inhibir la funcion de la proteina g y para el tratamiento de enfermedades proliferativas, composicion farmaceutica que los comprende y el uso de dichos compuestos para la manufactura de medicamentos
AR013506A1 (es) Uso de una composicion farmaceutica para la manufactura de un medicamento para ser usado en el tratamiento de enfermedades de obstruccion pulmonarcronica y de un kit que comprende formoterol o una sal o solvato del mismo y budesonida
CA2200754A1 (en) Process of making dosage units by wet granulation
BR9610089A (pt) Microemulsão não tóxica de óleo em água ou bicontínua processo para sua preparação e uso da mesma
FI953748A0 (fi) Yhdisteitä, joilla on sekä voimakas kalsium antagonisti- että antioksidanttiaktiivisuus sekä niiden käyttö solua suojaavina aineina
BR0109966A (pt) Combinação de compostos orgânicos
CA2004239A1 (en) Use of acetyl d-carnitine in the therapeutic treatment of glaucoma, and pharmaceutical compositions useful in such treatment
ATE211384T1 (de) Verwendung von adenosinantagonisten zur vorbeugung und behandlung von pankreatitis und ulcera
FI971188A0 (fi) Terapeuttinen vitamiini-kalsium yhdistelmä yksikköannoksena galeenisen tabletin muodossa, menetelmä sen valmistamiseksi ja sen käyttö
MX9802849A (es) Una composicion antibacteriana para administracion oral.
CA2215234A1 (en) Composition containing amlodipine, or its salt and an ace inhibitor
BR0109515A (pt) Derivados da apomorfina e métodos para seu uso
DE69908421D1 (de) Pharmazeutische zusammensetzung enthaltend eine kombination der dextro- und laevo-isomeren von sotalol
CA2160132A1 (en) Use of steroid antagonists for the therapy and prophylaxis of demential illnesses
ITRM950273A0 (it) Antagonisti di interluchina-6 umana del tutto incapaci di formare un legame con gp 130, e loro uso per la preparazione di composizioni farmaceutiche.
ES2061977T3 (es) Compuestos analogos a bradiquinina, su sintesis y su uso en terapia.
IT1238356B (it) Derivati gangliosidici, loro uso quali agenti terapeutici, procedimento per la loro produzione e composti farmaceutici che li contengono.
CA2322229A1 (en) Compositions comprising heparin and soluble tnf receptors for inhibition of tnf activity
CA2299464A1 (en) Controlled release pharmaceutical compositions containing tiagabine
IE840977L (en) Pharmaceutical preparations
Daudon et al. Drug nephrolithiasis: an unrecognized and underestimated pathology
ES8801267A1 (es) Procedimiento para preparar derivados de isoquinolinona

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 521388

Country of ref document: ES